Difference between revisions of "Ravulizumab (Ultomiris)"
Warner-admin (talk | contribs) m (Text replacement - ": new" to ": New") |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | ||
| + | |||
| + | ==Toxicity management== | ||
| + | *[https://ultomirisrems.com/ Link to REMS program] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 35: | Line 38: | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
[[Category:EMA approved in 2019]] | [[Category:EMA approved in 2019]] | ||
| + | [[Category:REMS program]] | ||
Revision as of 12:27, 18 August 2023
General information
Class/mechanism from the NCI Drug Dictionary: A longer-acting antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, ravulizumab-cwvz binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). Compared to other anti-C5 antibodies, ALXN1210 is longer-acting and allows for monthly dosing.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Toxicity management
Diseases for which it is used
History of changes in FDA indication
- 2018-12-21: Initial approval for adult patients with paroxysmal nocturnal hemoglobinuria (PNH). (Based on ALXN1210-PNH-301 & ALXN1210-PNH-302)
History of changes in EMA indication
- 2019-07-02: Initial authorization
History of changes in PDMA indication
- 2020-09-25: New indication and a new dosage for the treatment of atypical hemolytic uremic syndrome (aHUS).
Also known as
- Code name: ALXN1210
- Generic name: ravulizumab-cwvz
- Brand name: Ultomiris